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Abstract
Background: Ethical and regulatory guidance on the collection and use of human biospecimens (HBS) for research
forms an essential component of national health systems in Sub-Saharan Africa (SSA), where rapid advances
in genetic- and genomic-based technologies are fueling clinical trials involving HBS and the establishment of
large-scale biobanks.
Methods: An extensive multi-level search for publicly available ethics regulatory guidance was conducted for each
SSA country. A second review documented active trials listed in the WHO International Clinical Trials Registry
Platform as of January 2015 in which HBS collection was specified in the protocol. Findings were combined to
determine the extent to which countries that are study sites for HBS-related research are supported by regulatory
guidance language on the collection, use, ownership and storage of biospecimens.
Results: Of the 49 SSA countries, 29 had some form of national ethics guidance, yet only 17 provided language relating
to HBS-related research, with specific guidance on consent (14), ownership (6), reuse (10), storage (9), and export/import/
transfer (13). Ten countries accounted for 84 % of the active clinical trials involving the collection of HBS in SSA. All
except one of these countries were found to have some national guidance in the form of regulations, codes of ethics,
and/or standard operating procedures; however, only seven of the ten offered any language specific to HBS.
Conclusions: Despite the fact that the bulk of registered clinical trials in SSA involving HBS, as well as existing and
proposed sites for biorepositories under the H3Africa Initiative, are currently situated in countries with the most
complete ethics and regulatory guidance, variability in the regulations themselves may create challenges for planned
and future pan-African collaborations and may require legislative action at the national level to revise. Countries in SSA
that still lack regulatory guidance on HBS will require extensive health system strengthening in ethics governance before
they can be full participants in the modern research enterprise.
Keywords: Sub-Saharan Africa, Biospecimens, Biobanks, Ethics guidance, Regulatory systems, Ethics committees, Health
systems, Materials transfer agreements
Background
Exponential growth in the fields of pharmacogenetics
and genomics research over the past decade is fueling
worldwide interest in the establishment of bioreposi-
tories of human biological specimens. Biorepositories
already exist in three SSA countries—The Gambia,
South Africa, Zimbabwe [1–3]. Major expansion in this
domain is occurring in Sub-Saharan Africa, largely
driven by the Human Heredity and Health in Africa
Initiative (H3Africa), a joint effort of the National Institutes
of Health (NIH), the Wellcome Trust, and the African
Society for Human Genetics [4]. The ‘hub and spoke’
model adopted by this initiative calls for the development
of four pilot regional biobanks – two in South Africa and
one each in Nigeria and Uganda – which will serve as
multi-country repositories of specimens collected under
sponsored research activities taking place throughout the
region [5]. The H3Africa Initiative reflects significant
efforts by the international community of researchers,
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funding agencies, and African academic institutions to
build a foundation for sophisticated, state-of-the-art
genomic research on burdensome diseases in Africa; the
ultimate goal of the initiative is to improve the health of
the African peoples.
From its inception, the initiative has sought broad
consensus on topics relating to ethics and governance A
Joint NIH and Wellcome Trust Policy document sets
forth high-level principles on ethics, governance, and re-
source sharing with which research networks and pro-
grams funded by the initiative are expected to comply
[6]. A standing working group on ethics and regulatory
issues comprising ethicists and other members of the
scientific community meets periodically to discuss and
develop recommendations on a wide range of topics
including community engagement strategies, cultural
issues, informed consent, participant safety, return of re-
sults, intellectual property, material transfer agreements,
and other regulatory issues. While such guidance has
the potential to serve as a model framework for all
countries in Africa to consider as they develop their own
national guidelines, the current focus of the initiative is
on those entities that it supports. Applied more broadly,
the pan-continental approach espoused by H3Africa and
similar initiatives may require a level of ethical guidance
at the country level explicitly addressing the collection
and use of HBS which is currently not to be found in most
national ethics regulatory guidance. In many African
countries, such systems are in their infancy; policies that
address emerging technologies such as whole genome
sequencing and association studies are absent [7, 8].
The International Declaration on Human Genetic
Data, promulgated by UNESCO in 2003, recognized the
importance of national policies to guide the collection,
processing, use, and storage of human genetic data, as
well as the review by local and institutional ethics com-
mittees of protocols involving such data [9]. In Africa
specifically, a growing body of literature has focused on
the need to have ethical and legal governance structures
in place to oversee research involving HBS and the oper-
ation of biobanks [10, 11].
If the H3Africa vision of a pan-continental genomic
enterprise is to be fully realized, ethics guidelines at the
national level must align in ways that support interoper-
ability among African countries. In cases where no
guidelines presently exist, investment in institutional
capacity-building by such entities as H3Africa and others
may be needed to support their development. In cases
where national guidelines do exist, some may require the
addition of new language specific to research involving
HBS; such revisions may require legislative approval.
There may be instances where national values simply will
not support the transnational transfer of genetic informa-
tion, broad data sharing within research communities
(however relevant to their populations), or the delegation
of decision-making on future use to an outside authority.
The lack of interoperability among African nations in their
ethics guidance as well as differences in interpretation of
meaning in instances where international recommenda-
tions have been adopted has the potential to slow, even
derail, the realization of benefit from new advances and
approaches in biomedical research [10, 12].
Although a number of scholars have examined the
ethical, legal, and social issues associated with the collec-
tion and use of biospecimens in research, there has been
far less focus on the existence and nature of regulatory
guidance on HBS at the national level in Sub-Saharan
Africa [8, 11–17]. Of particular importance is the identi-
fication of national ‘gaps’ in ethics guidance, as well as
inconsistencies and national differences among those
countries where guidance does exist.
Methods
This study involved two systematic reviews designed to
determine the availability of publicly accessible regulatory
HBS guidance at the national level in SSA countries and
to assess the extent to which it addressed ethical and regu-
latory issues relating to consent, ownership, reuse, storage,
and export/import/transfer. Two reviews were conducted
as part of this project. The first involved a multi-level
search to identify publicly available national research
ethics guidance on the collection and use of HBS in
countries in Sub-Saharan Africa. This process, detailed in
Table 1, involved keyword searches, on-line reviews of
international ethics databases and regional and national
government websites, and, in those instances where on-
line efforts yielded no results, direct contact via email with
national ethics committees and scans of ethics review
statements included in previously published journal.
National ethics guidance was operationalized to include
enabling legislation for the creation and constitutions of
national research institutes and national research ethics
committees, codes of ethics, national ethics guidelines,
and standard operating procedures. We excluded those
documents that only provided instructions to researchers
on how to submit their protocols, instruction on writing
consent documents, and organizational information from
research ethics committees that were not identified
as being national in jurisdiction. Materials Transfer
Agreements (MTA) and Specimen Transfer Agreements
(STA) for specific countries were included in our search
but were only used as a source of guidance if we could
find a specific reference to “human” biological specimens.
We limited our results to those national documents that
we could access publicly on-line or secure through contact
with the national regulatory body, reasoning that guide-
lines that were inaccessible via such mechanisms would
be of limited utility to the research community.
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A second review was conducted using the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) to iden-
tify registered clinical trials taking place in Sub-Saharan
Africa as of January 1, 2015, and, of these, the number of
clinical trials in each country that called for the collection of
HBS as part of the study protocol [18]. The ICTRP is a
web-based, publicly accessible compilation of studies that
have been registered in any of the following databases:
Australian New Zealand Clinical Trials Registry (ANZCTR);
Chinese Clinical Trial Registry (ChiCTR); ClinicalTrials.gov;
EU Clinical Trials Register (EU-CTR); ISRCTN; The
Netherlands National Trial Register (NTR); Brazilian
Clinical Trials Registry (ReBec); Clinical Trials Registry –
India (CTRI); Clinical Research Information Service -
Republic of Korea (CRiS); Cuban Public Registry of
Clinical Trials (RPCEC); German Clinical Trials Register
(DRKS); Iranian Registry of Clinical Trials (IRCT); Japan
Primary Registries Network (JPRN); Pan African Clinical
Trial Registry (PACTR); Sri Lanka Clinical Trials Registry
(SLCTR); and Thai Clinical Trials Register (TCTR).
Included in the count of active clinical trials were those
trials listed in the database as active/not recruiting;
recruiting; not yet recruiting; authorized-recruitment/may
be ongoing or finished; and pending. Studies were ex-
cluded if identified as not recruiting; complete; termi-
nated; closed/follow-up continuing; closed to recruitment/
follow-up complete; temporary halt or suspension; other;
not applicable; or withdrawn. The process used to identify
active trials calling for HBS collection is illustrated
in Fig. 1.
Results
Table 2 summarizes the availability of national ethics
guidance irrespective of content as well as guidance
language specific to HBS in each of the 49 countries
Fig. 1 Research process for identifying active clinical trials in SSA
involving HBS collection (Source: WHO-ICTRP as of January 1, 2015)
Table 1 Search strategy and selection criteria
Level Components of search
Level 1 Search Engines: Google, Google Scholar, PubMed, National Library of Medicine
Keywords: Name of country + each of the following terms:
human biological specimens, biobanks, ethics regulations, research ethics, ethics regulations, ethics committee, bioethics, consent, human
subjects research, drug regulation, research regulations, institutional review boards, ethics review committees, materials transfer
agreement
Level 2 On-line directories:
Canadian Coalition for Global Health Research (CCGHR). www.ccghr.ca
Harvard Research Ethics Guidelines International Online Navigation Map (REGION). https://www.hsph.harvard.edu/region-map/
Health Research Web (HRWeb). https://healthresearchweb.org/en/africa
Office for Human Research Protections (OHRP). International Compilation of Human Research Protections. http://www.hhs.gov/ohrp/sites/
default/files/internationalcomp2016%20.pdf
Training and Resources in Research Ethics Evaluation (TRREE). http://elearning.trree.org/
UNESCO – Assisting Bioethics Committees (ABC) http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/assisting-
bioethics-committees/
UNESCO Global Ethics Observatory. http://www.unesco.org/new/en/social-and-human-sciences/themes/global-ethics-observatory/
WHO African Health Observatory (Health Systems) http://www.aho.afro.who.int/en/atlas/health-system
WHO MINDbank. https://www.mindbank.info/
Level 3 Web sites of regional ethics organizations:
Pan African Bioethics Initiative (PANBIN). http://www.who.int/sidcer/fora/pabin/en/
Level 4 Direct contact via email with National Ethics Committees in Sub-Saharan African countries
Level 5 1. Scan of journal articles on biomedical research in specific SSA countries to identify:
a. Ethics Review Statement: Name of African REC, if any, that conducted an ethics review of research protocol
b. Names of US researchers who have worked in that particular African country
2. Check web for identified IRB/ERC/approval granting regulatory body
3. Contact individual researchers by email to request information about IRB reviewing procedures and familiarity with regulations (if any)
governing collection and use of HBS.
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Botswana ● ● ● ● ● ● ● ●













Ethiopia ● ● ● ●
Gabon ●
The Gambia ● ● ● ● ● ● ● ●
Ghana ●
Rep. of Guinea ●
Guinea- Bissau
Kenya ● ● ● ● ● ●
Lesotho ●
Liberia ● ● ● ●
Madagascar ●







Nigeria ● ● ● ● ● ●
Rwanda ● ● ● ● ● ●
Sao Tome & Principe
Senegal ●
Seychelles
Sierra Leone ● ● ● ● ●
Somalia
South Africa ● ● ● ● ● ● ●
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included in the WHO region constituting Sub-Saharan
Africa. Detailed information on the specific content of
any HBS-related language is provided in Table 3.
Twenty-nine (60 %) of the countries in the region had
some national ethics guidance, either in the form of
laws, regulations, codes, guidelines, or standard operat-
ing procedures. Of these 29 countries, however, twelve
did not have regulations that addressed specific guiding
principles or rules for ethics research or review. Six
(Congo DRC, Equatorial Guinea, Republic of Guinea,
Lesotho, Madagascar, and Mali) had regulatory language
that was limited to establishing or defining the functions
and constitution of research ethics committees. One
(Mauritius) had drafted a code of research ethics that
was distributed for public comment in 2003, but no
documentation could be found that it had been opera-
tionalized. Three countries (Cameroon, Mozambique,
Rwanda) offered limited language specific to guiding
principles or ethical conduct of research, but link their
review processes to the ethical guidance contained in
the Declaration of Helsinki, CIOMS, or the ICH-GCP
[19–21]. No national guidelines for general ethical con-
duct of research could be found for The Gambia, but
the Medical Research Council – The Gambia had pub-
lished very detailed guidelines for the collection and use
of biospecimens stored in the National DNA Bank of
The Gambia which we have included in our analysis
[22]. In addition, two countries (Chadand Gabon) had
been working with UNESCO on the establishment of na-
tional ethics committees but no regulatory documenta-
tion could be found [23, 24].
More than one half (59 %) of the countries whose
guidelines articulated ethical principles or guidelines
for ethical review include some language to guide the
collection and use of HBS for biomedical research.
Fourteen of these offered some language with respect
to informed consent; 10 addressed the subject of reuse;
and 12 contained specific language relating to export/
import/transfer. Only six countries offered language
with respect to HBS ownership and nine contained
language regarding storage. Thirteen required that a
Materials or Specimens Transfer Agreement be exe-
cuted. Table 4 reports the findings with respect to reg-
istered, active clinical trials in Sub-Saharan Africa that
called for the collection of HBS. Of the 5319 studies
identified in the WHO International Clinical Trials
Registry Platform, 1802 of were currently active as of
January 1, 2015. Three hundred sixty-six (366) of these
involved the collection of a biosample from research
subjects. The distribution of these trials across the re-
gion are illustrated in Fig. 2.
Table 5 reports on the ethics system guidance on HBS
found in the countries where the largest number of stud-
ies involving HBS are currently taking place in Sub-
Saharan Africa. These 10 countries account for nearly
82 % of the active clinical trials involving the collection
of HBS in the region that were registered in the WHO
International Clinical Trials Registry Platform as of
January 1, 2015. They included the five countries that
either have existing biorepositories (The Gambia, South
Africa and Zimbabwe) or planned to establish regional
biorepositories in the near future as part of the
H3Africa Initiative (Nigeria, South Africa and Uganda).
All ten of these countries had some form of ethics
system guidance in the form of regulations, codes of
ethics, standard operating procedures, or guidelines,
and, with the exception of Mali, provided some regula-
tory language at the national level as to the collection
and use of HBS. Notably only four of these countries
(The Gambia, Kenya, Uganda, and Zambia) included
language in their national ethics documents on the
ownership of HBS. Mali, where at the time of our study
there were currently 10 registered active trials requiring
a biosample, had no guidance language on HBS in its
national ethics documents. Although most of the coun-
tries in which large biorepositories existed or are
planned as part of H3-Africa contain fairly detailed
HBS language in their guidelines, only two (The
Table 2 SSA countries with HBS-related information in legislative/regulatory/guidance ethics documents (Continued)
South Sudan
Sudan ● ● ● ●
Swaziland
Tanzania ● ● ● ● ● ● ●
Togo
Uganda ● ● ● ● ● ● ● ●
Zambia ● ● ● ● ● ● ● ●
Zimbabwe ● ● ● ● ●
TOTAL 29 17 14 6 10 9 12 13
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charge et contrôle du
VIH/SIDA (2006) [28]
Loi No. 2010-40 portant
code d'éthique et de
déontologie pour la
recherche en santé en




charge et conttrolé du
VIH/SIDA en Republique
du Benin (2005)
Loi No. 2010-40 Portant
code d'éthique et de
déontologie pour la
recherche en santé en
République du Bénin (8
December 2010).






Substance Act, 1992 [31]
Botswana Drugs Advisory




















waived by an ethics
committee." (MOH SOPs,
2011, 7.2.iv)
An ethics committee may
sometimes waive, with or
without conditions, the
requirement for consent.
(MOH SOPs, 2011, 7.2.v)
Acquisition, storage and
future use of biological
materials: Informed
consent process and
forms separate from and





is normally the owner of
research data. The creators
of the data, the Principal
Investigators and local
institutions in Botswana
should hold the data in





has to apply to the HRDC
regarding the decisions
about use and sharing
of their data with other
researchers and
institutions according to
Botswana law (MOH SOPs,
2011, 8.5.Appendix 11)."
Research protocols should
detail the purpose and
use of research specimens
Where archived
specimens are required in
another experiment,
researchers must provide
a new protocol for review
and approval by HRDC.




and should hold samples




subjects have right to




required for use, transfer,
storage & future use
according to Botswana
laws.
Where samples have not
been obtained as part of
research, the institution
that collected them takes
custodianship of them.
Any future study on such
samples is subject to
review by HRDC. (MOH
SOPs, 2011, 8.2)
No transfer unless: a) the
researcher and the other
research group are
collaborating on research
that has been approved
by an ethics committee;





material may be approved





importation) of HBS for
research purposes shall
require clearance from the
HRDC. (MOH SOPs, 2011,
8.3)
Procedures for Exchange/
Transfer of HB Materials,













Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Burkina Faso
Law No. 23/94/ADP of 19





Minister of Health, the






functioning of the Ethics
Committee for Health
Research in Burkina Faso.
[36] (Decree contains no
research ethics regulatory
guidance.)
A draft Code of Ethics was
written in 2005 but there
is no publicly available





products that can be used
for therapeutic or research
purposes on human
beings. They can be
























informed that this policy
exists and that their
privacy and confidentiality
will be protected. (p. 105-
106).
Page 106 specifies
information that must be
contained in a consent
document for a study
involving human genetic
research. (Joint Order No.
2004)
No language No language No language No language
Burundi
None found None found None found None found None found None found None found
Cameroon
Arrêté No. 079/A/MSP/DS-
Order of the Minister of
Public Health, October 22,
1987: Creation and




No language No language No language No language No language No language
















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
(Article 9 refers to an
evaluation process relying
on Declaration of Helsinki)
Decision 0674/D/MSP/
CIRCB, October 13, 2006:
Creation and functions of







None found None found None found None found None found None found None found
Central African Republic
None found None found None found None found None found None found None found
Chad
Part of UNESCO Bioethics





None found None found None found None found None found None found
Comoros
None found None found None found None found None found None found None found
Republic of Congo





systems de santé en RDC
(June 2004) [39]
No language No language No language No language No language No language
Côte D’ivoire
None found None found None found None found None found None found None found
Djibouti



























No language No language No language No language No language No language
Eritrea
None found None found None found None found None found None found None found
Ethiopia
FDRE Ministry of Science
& Technology; National
Research Ethics Review




Guideline 8.3.2, p. 51-52
IC process should include
info on HBS and data to
be collected, data
anticipated to be derived
from sample as well as
health and other records
to be accessed, their
intended uses, storage
and duration of storage.
Participants must be
informed that specific
information will not be
shared with family
members, and that, if
shared with third parties,
will be anonymized.
Participant should be
given option of allowing
sharing of samples or not.
(Guideline, 8.3.2., p. 52)
Separate consent form for
HBS collected for storage
and/or future use.
Participant may choose
whether to have HBS
stored for future studies.
(Guideline, 9.2, p. 57)
Host institution in Ethiopia
holds HBS in trust on
behalf of research
participant. (Guideline, 9-2,
p. 58) Where HBS have
not been obtained as part
of research, the institution
that collected the samples
takes custodianship.
(Guideline 9.2, p. 58)
Any shared samples must
be anonymized to the
recipient, Use of HBS
beyond what is stated in
original protocol must
have consent of research
participants or their
representatives. Secondary
use may only be done on
anonymized samples and
after getting approval by
the IRB. When subsequent
use of HBS or data is
proposed that is not
consistent with original I/
C, a new consent should
be obtained from
participant/guardian or
LAR or a waiver of
consent should be
requested from IRB.
(Guideline, 8.3.2, p. 52)
Intent to store HBS and
place and duration of





to withdraw their HBS
from storage if samples
are linked. (Guideline, 9.2)





sharing, a framework for
accessing and sharing
data, restrictions to third
party transfers, and annual
reports to host institution.
An Ethiopian scientist
must be included as a co-
investigator in all future
studies using the HBS. The
IRB in Ethiopia must
review all research studies























Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)





Dept. of State for Health &
Welfare; National Health
Research Policy[revised
draft for discussion: 29/10/
2009] [43]
Dept. of State for Health &
Welfare; National Health
Research Strategic Plan
2010-2014 [final draft: 15/
01/2010] [44]
Guidelines for The Gambia
National DNA Bank, 2001
[22]
Samples from children
only after permission from
parents or guardians No





Permission from donor for
reuse of samples that
have not been
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depending on whether or
not requested specimens
have been anonymized,






The Gambia National DNA
Bank was established in







researchers and the DNA
Bank, with approval of
Committee. Agreement
must describe analyses to
be undertaken with
specimens; feedback must
be given to MRC Labs,
results of analyses must
eventually be placed in
the public domain, and
any manuscripts resulting








Public Health Act 2012
[Act 851] Good Clinical
Practice Doc No FDA/
SMC/CTD/GL- GCP/2013/
02 Ver. 2, 18 Dec 2015
(Adopted 27 Jan 2016)
[45]





and Organization of the
National Ethics
Committee for Research
in Health (CNERS) (Decree
No D/218). 1998. [46]
Decree contains no ethics
regulatory guidance
language.
No language No language No language No language No language No language
Guinea-Bissau
















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Kenya
The Science, Technology
and Innovation Act, 2013





Human Subjects in Kenya















clinical trials in Kenya,
2011. [50]






ERC to determine whether
or not individual informed
consent is needed for
studies involving "left-
over" HBS (Natl Guidelines
2004)
Applications for clinical



















No language No biological material
transfer is permitted
without the informed
consent of the trial
participants and without
approval of protocol and
in accordance to Ministry
of Health guidelines on
transfer of HBS. (Vaccine





must state that specimens
will only be used for
scientific, educational,
non- commercial use. Any
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Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Liberia
Ethics approval required
from one of three REC




NHSREC), the University of
Liberia Institutional





Institute for Research and
Evaluation: Institutional
Review Board (IRB) Policies
and Procedures Handbook




to Conduct Clinical Trials in
Liberia 2014. [54]
Research involving the
collection or study of
pathological specimens,
or diagnostic specimens
may be exempt, if those
sources are publicly
available or if the
information is recorded
by the investigator in




identifiers linked to the
subjects.
Archival research in which
individual subjects could
potentially be identified is
not exempt. (University of
Liberia, Policies &
Procedures Handbook,
2008, Art. 5 pg. 23)
Applications for clinical
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SAN (May 8, 2000)
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in 2007 and 2012
documents.
Informed consent for HBS
required. Persons may
only be consented for
HBS collection for
purposes of answering
the study objectives of a
presently intended study
that has been clearly
defined.(Policy
Requirements, 2007, 10.0)
No language All forms of studies &
testing aimed at



















collection, use, storage of
specimens for future use,
HBS may be stored for
future analysis as specified
in a presently intended
study approved by NSTC
but not for a period to
exceed five years.
Additional time period
may be granted. (Policy
Requirements, 2007, 10.0)
Analysis of specimens
should be done within
Malawi by local
technicians/professionals.
Export permitted only in
exceptional circumstances
when the needed
technology does not exist
in Malawi nor can it be
imported or when tests
are needed to confirm
results and/or quality





specify why export is
necessary, its intended
use, length of time HBS
will be kept, and name of
local technician/





No. 02-200/P-RM April 22,
2002-
Creation of a National
Ethics Committee for
Health and Life Sciences
[58]
Minister of Health-
Internal Ruling August 26,
2004- Operation and
Functions of Ethics
Committee for Health and
Life Sciences. [59] Loi 86-
11 N RM Fundamental
Principles of Scientific and
Technological Research
[60] (Documents contain
no ethics guidance for
conduct of research.)
















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Organization and
functions of the National
Institute of Public Health
Research, including




None found None found None found None found None found None found None found
Mauritius
The Clinical Trials Bill (Feb
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No language No language No language No language No language No language
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principles (Dec. of Helsinki,
CIOMS, ICH-GCP.)
















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Namibia




Committee but it is not
operational. [64]
None found None found None found None found None found None found
Niger

















Policy, 2013) NHREC to




Biobanks in Nigeria must
retain copies of all
consent forms and these





in which the type or
purpose of research is
defined in broad terms
and for a work that is not
specified by time (Section
E.1, Biobanks, 2013)
No language No language Any samples kept more
than 2 months post-
analysis are considered
'banked' and covered by
Biobank Policy. Copies of
all participant I/C forms
must be available and can




to MTA approved by
HREC. Institutional HRECs
shall grant final approval
for research involving
international transfer of













to HBS (Sections 35 & 36




HBS must be collected
with free and informed
consent even if tissue is
obtained as part of
patient care. Consent
forms must indicate if HBS
is being collected for
current research only,
how long the specimens
will be kept, and when
they will be destroyed. If
HBS is stored longer than
the current research, then
a separate permission for
storage must be obtained.
Under MTAs: Ownership is
the "Provider of the
samples." Ownership
of any income resulting from
commercialization must
be negotiated in good
faith (Rwanda SOPs, 2009,
Appendix 7).
No language No language MTAs are required. Entities
to whom HBS is
transferred must provide
any resultant publications,
and provider must be part


















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Sao Tome & Principe
None found None found None found None found None found None found None found
Senegal
Arrêté ministerial No. 3224





Loi No. 2009-17, March 9,
2009:
Code of Ethics for Health
Research. [70]
Règlement Intérieur du





No language No language No language No language No language No language
Seychelles
None found None found None found None found None found None found None found
Sierra Leone





and Medical Devices in
Sierra Leone (Version 02)
(G-SLClinTrial). 2014. [72]
Pharmacy Board of Sierra
Leone: Guideline for Good
Clinical Practice (GCP) in
Sierra Leone (Version 01)
(SL-GCPs). 2014 [7373]
Ministry of Health &
Sanitation, Office of the









clinical trials, 2014, p. 20-
21)
Definition of HBS: a










Separate consent for use
of HBS (Guidelines, 2014,
Sec. 3.9.1)
HBS taken in course of
clinical care may be used
for research without
consent subject to ethics
committee review.
Patients have right to
know their HBS is being
used for research. Patient
refusal to such use does
not warrant waiver of
consent.
Refusals to be honored




No language Secondary use of HBS is
constrained by conditions
specified in initial consent.
Therefore, initial consent
should specify whether or








No language Materials Transfer
Agreement is required.
(NIAID Communication
with the Pharmacy Board


















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Somalia
None found None found None found None found None found None found None found
South Africa
Act 61 of 2003 National
Health Act [75]
Regulations Relating to
the Use of Human
Biological Material, March
2012 [76]
Chapter 8, Sections 53-68.
(National Health Act,
2003) Regulations Relating
to the Use of HBS (2012)
Written informed consent
of individual with provisions
for consent from subjects
who are minors or mentally




information and for long-
term storage of genetic
material, stem cells, or
research findings
(Regulations, 2012, 13.d & f).
No language HBS information used for




of the user or donor for
long term storage of
genetic material, stem




consent prior to release of
stored information.
(Regulations 2012, 13e & f).
Export permit is required.
No export unless it is
established that sample
was donated under terms
of Act and will be used in
accordance with terms of
Act. (Act, 2003, 8.68.1(g))
South Sudan







Guidelines, 2008, Secs. 5.2,
5.10, & 5.11).
Investigator must provide
subjects: policy to use results





possible research sites, direct
or secondary use of HBS
taken in course of clinical
care (5.2.18); disposal, storage,
future use of HBS (5.2.19);
any commercial products
from HBS and distribution of
any revenues (Guidelines,
2008, 5.2.20) Consent forms
must have separate sections
requesting use of HBS for
research purposes
(Guidelines, 2008, 5.10)
HBS taken in course of
clinical care may be used
























Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)
Swaziland





Guidelines of Ethics for
Health Research in
Tanzania, 2nd ed., 2009.
[24]
The Human DNA











study only. New protocol
required for reuse
(Guidelines, 2009, 8.8)
No collection of a sample
without the
consent of the sample
source (DNA Act,
2009, 38-41).
Samples of Human DNA
are the property of the
sample source. (DNA Act,
2009, 28.2.b)
Where the research results
from an individual or an
institute are new or
unique, the researcher or
the institute shall have the
intellectual property rights
(DNA Act, 2009, 5.3.7).
Consent for intended
study only New protocol












within one month notify
of their intent to reuse
and secure the permission
of sample source or (b)
destroy samples within
three months (38.44, DNA
Act, 2009, 38.44)
No language Materials transfer
agreement is required.
Togo













See Guidelines 2014, Sec.
10., pp. 28-31.
Consent must include
explanation of how HBS
will be managed at end
of study. If stored,
separate consent must be







Sample sources own the
samples If samples are
identified, source may
withdraw them at any
time. Samples to be held
in trust by duly authorized
Uganda organization.
Trustee organization has
authority to decide use,
transfer, storage and
future use of HBS in its
care, taking into account
rights and welfare of
research participants
(Guidelines, 2014, 10.3)
A Ugandan scientist must
be included on all future
studies. Separate informed
consent document
required for each reuse
(See HBS, I/C). All future





must be traced and
consent for research use
secured. (Guidelines,2014,
10.2)
See HBS I/C MTA required. Future use
of HBS subject to review
and approval by an REC in
provider's country.
(Guideline, 2014, 10.4)
Applicant for transfer must
be a legal resident of
Uganda and affiliated with





demonstrate lack of in-
country capacity to
perform tasks. Sample may
















Table 3 National regulatory guidance language on collection and use of HBS by country* (Continued)


















Research Act 2013 [83]




Minister of Health may
designate specific sites as
biobanks
No HBS removed from
living person for health
research purposes without
written consent of donor
in accordance with
provisions of the Act. Act,
Art. 47 (1)
Ownership specified in
MTA as determined by
Minister of health in
consult with Health
Authority. Act, Art. 51
(1)(a)
A person shall not
withdraw HBS from a





A person shall not
withdraw HBS from a





Storage not to exceed
10 years without special
approval of longer period
from Health Authority Act,
Art. 51 (2) (b)
Only with written approval
of the National Health
Research Authority Act,
Art. 50 (1) and if terms of
MTA are met Art. 50 (2)





















as of 1/3/15) [86]
Discussion of HBS not
included in MRCZ
guidelines.




period is illegal. RCZ STA,
2015)
Note: All international




No third party transfers.






































Angola 3 2 0 2 2 0 2
Benin 33 10 1 11 2 1 3
Botswana 50 10 5 15 4 1 5
Burkina Faso 117 20 11 31 3 1 4
Burundi 0 0 0 0 0 0 0
Cameroon 57 12 6 18 1 1 2
Cape Verde 0 0 0 0 0 0 0
Central
African Rep.
6 5 3 8 0 0 0
Chad 0 0 0 0 0 0 0
Comoros 0 0 0 0 0 0 0
Republic of Congo 59 10 3 13 3 0 3
Congo (DRC) 17 10 2 12 1 0 1
Cote d’Ivoire 37 10 4 14 3 0 3
Djibouti 0 0 0 0 0 0 0
Equatorial
Guinea
0 0 0 0 0 0 0
Eritrea 1 0 0 0 0 0 0
Ethiopia 74 22 7 29 2 3 5
Gabon 34 5 0 5 1 0 1
The Gambia 79 11 4 15 5 1 6
Ghana 138 33 7 40 10 1 11
Guinea 74 1 2 3 0 0 0
Guinea-Bissau 43 5 9 14 2 5 7
Kenya 320 65 27 92 17 4 21
Lesotho 0 0 0 0 0 0 0
Liberia 7 1 1 2 0 0 0
Madagascar 12 1 0 1 1 0 1
Malawi 171 33 15 48 7 4 11
Mali 101 20 7 27 7 3 10
Mauritania 5 3 0 3 0 0 0
Mauritius 9 2 1 3 0 0 0
Mozambique 52 11 1 12 2 1 3
Namibia 0 0 0 0 0 0 0
Niger 19 7 1 8 2 0 2
Nigeria 103 37 7 44 10 2 12
Rwanda 57 8 1 9 2 0 2
Sao Tome &
Principe
0 0 0 0 0 0 0
Senegal 58 10 3 13 2 0 2
Seychelles 2 0 1 1 0 1 1
Sierra Leone 11 3 3 6 1 2 3
Somalia n.d. n.d. n.d. n.d. n.d. n.d. n.d.
South Africa 2712 832 234 1066 150 39 189
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Gambia and Uganda) spoke to issues of ownership.
After Mali, Zimbabwe offered the least guidance within
this group of countries, with no language on HBS-
specific consent, ownership, or reuse.
Discussion
This study examined the availability of national ethics and
regulatory guidance on biomedical research in Sub-
Saharan African countries and identified the extent to
which national regulatory systems provided ethics guidance
on specific aspects of HBS collection and use to inform
research design and ethics review. Ethical principles and
regulatory guidance regarding HBS consent, ownership, re-
use, storage, and export/import/transfer are foundational
elements in national health systems as research activities
calling for the collection and use of biospecimens in Africa
expand and ethics committees are increasingly called on to
review and respond to rapidly advancing innovation in
research and research technologies.
Our research found that despite efforts at the inter-
national, regional, and national levels, 20 of the countries
in Sub-Saharan Africa (41 %) at the time of our study still
lacked articulated national ethical principles and regula-
tory guidance for policy-making, review, and monitoring
of research. Among those countries where ethical and
regulatory guidance existed, specific language with respect
to HBS collection and use was often lacking or incom-
plete. While in 17 of the countries in Sub-Saharan Africa
Table 4 Clinical trials in SSA involving HBS collection (Source: WHO-ICTRP as of January 1, 2015) (Continued)
South Sudan 0 0 0 0 0 0 0
Sudan 0 0 0 0 0 0 0
Swaziland 7 4 0 4 1 0 1
Tanzania 263 45 14 59 10 3 13
Togo 8 5 0 5 0 0 0
Uganda 351 74 25 99 20 4 24
Zambia 147 31 11 42 5 4 9
Zimbabwe 82 23 5 28 7 2 9
Total 5319 1381 421 1802 283 83 366
No data (n.d.)
Fig. 2 Distribution of active clinical trials in SSA involving HBS collection (Trial information Source: WHO-ICTRP as of January 1, 2015; Map source:
Wikimedia Commons)
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(59 %), some form of national regulatory guidance relating
to HBS did exist, a number of these lacked explicit guid-
ance on HBS-related issues such as consent (3), ownership
(11), reuse (7), storage (8), and export/import/transfer (5).
Gaps in national ethical and regulatory guidance in the
region on the collection and use of HBS for research
may result in inconsistent reviews within ethics commit-
tees and pose challenges for full participation by African
countries in genomic research. In the absence of guiding
principles and regulatory direction, ethics committees
may delay or deny HBS-related research of potential
benefit to their communities, or they may approve such
research without due exploration of its implications for
its citizenry or its cultural values.
Differences in ethical and regulatory requirements among
African countries where guidance does exist also appear to
raise impediments to the interoperable pan-African ap-
proach to genomic research espoused by H3Africa. Despite
the fact that the bulk of registered clinical trials involving
HBS in Sub-Saharan Africa, as well as existing sites and
those sites proposed for future biorepositories, are currently
situated in countries with the most complete ethics and
regulatory guidance on HBS, variability in the regulations
themselves may create challenges for pan-African collabo-
rations that rely on transnational sharing of specimens and
data or that delegate decision-making responsibility with
respect to future use to repository-centric ethics or scien-
tific review committees. Malawi, for example, contained
language in its guidelines that all forms of studies and
testing aimed at collecting and storing HBS for future
unspecified genetic research/analysis is ‘non-permissible’
[25]. Tanzania required that a new consent be secured for
each new research protocol in which a sample will be
reused [26]. Uganda, where one of the H3Africa repositor-
ies is intended to be located, required that all requests for
transfers of HBS be made by a legal resident of Uganda
who was affiliated with a locally registered and recognized
Ugandan organization [27].
While these and other potential sources of regulatory ten-
sion may be resolved in the future, for now they represent
potential constraints on research that calls for a more ‘re-
gional’ perspective of specimen and data sharing, and are
likely to require legislative action at the national level to
revise. At the same time, gaps in HBS-related guidance
within countries that are already research-intensive
sites may give rise to lengthy or inconsistent review de-
cisions by local ethics committees left to make their
own policy decisions in the absence of clearly stated
regulations or principles at the national level.
Future growth in the fields of pharmacogenetics and
genomic research is likely to generate demand for HBS
from a more representative pool of the African peoples
and to prompt researchers to look for new communities in
countries where research is currently not active. The trans-
national movements of diseases themselves, as seen in the
2014 Ebola outbreak in Western Africa, may identify new
target populations for study beyond those of interest at
present. Such expansion will require system-wide capacity-
building in these settings and will need to be guided by
clearly articulated national regulatory guidance to ensure
ethical and thoughtful research governance.
Resources to assist national governments in develop-
ing ethics capacity may be available through such pro-
grams as UNESCO’s Assisting Bioethics Committees
(ABC) program, which aims to build and strengthen
bioethics infrastructure within its member states and
which is already working to build capacity in Chad,
Gabon, and Madagascar [23, 24, 28]. H3Africa’s work-
ing group on ethics and regulatory issues and its work
to date in articulating broad principles and regulatory
guidance regarding HBS collection and use [6] would,
were its focus to extend beyond its own funded














Ethics system guidance specific to HBS
Consent Ownership Reuse Storage Export MTA
South Africa 189 ● ●● ● ● ● ● ● ● ●
Uganda 24 ● ● ● ● ● ● ● ● ●
Kenya 21 ● ● ● ● ●
Tanzania 13 ● ● ● ● ● ● ●
Nigeria 12 ● ● ● ● ● ● ●
The Gambia 11 ● ● ● ● ● ● ● ● ●
Malawi 11 ● ● ● ● ● ● ●
Mali 10 ●
Zambia 9 ● ● ● ● ● ● ● ●
Zimbabwe 9 ● ● ● ● ● ●
Total 309 3 4 10 9 8 4 7 8 8 8
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research networks and programs, be a valuable starting
point for countries as they begin to build national con-
sensus on the value of genomics research for their com-
munities and the region as a whole.
Limitations of this study
Data used in this study were largely derived from pub-
licly accessible sources. Despite an extensive search,
some of the countries in Sub-Saharan Africa that we re-
port as lacking national ethics regulatory guidelines may,
in fact, have them. Given the central role that national
policies play in shaping the research landscape in the
region, it is important that researchers and ethics com-
mittees have ready access to country-level guidance on
the collection and use of HBS as the scope of genomics
research in Sub-Saharan Africa expands. In addition, the
mapping of active clinical trials that involve HBS in Sub-
Saharan Africa relied on publicly accessible international
registries. It therefore did not take into account those
studies which are not required to register, and serves
more as an illustration of a potential regulatory ‘gap’
between research and national governance than as a
comprehensive source of data on HBS-related research
in the region.
Conclusion
Despite substantial capacity-building efforts, many coun-
tries still lack regulatory guidance on the collection and
use of human biological specimens in research. Al-
though the African countries currently most in demand
as HBS-related clinical research sites number among
those offering the most guidance, extensive health sys-
tem strengthening will be needed to ensure that regula-
tory language is available to guide the ethical extension
of HBS-related research into other countries in the re-
gion. Efforts to create interoperability across national
policies to meet international and regional research goals
of Pan-African research collaboration must be on-going,
recognizing that some differences may be value-based
choices by representative governments while others,
although malleable to change, will require legislative
action to amend.
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